ClinicalThought
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
From Clinical Care Options (CCO) and Dr. Robert Sidbury, expert commentary on new data in atopic dermatitis evaluation and management.
Robert Sidbury, MD, MPH
Released: June 30, 2021
Assessment of antipruritic properties of ruxolitinib cream using pooled data from TRuE-AD1 and TRuE-AD2: atopic dermatitis conference coverage from Clinical Care Options (CCO)
Assessment of depth, rapidity of response of abrocitinib and dupilumab in patients with moderate to severe AD in JADE COMPARE using stringent endpoints: atopic dermatitis conference coverage from Clinical Care Options (CCO)
Characterization of skin pain in children with atopic dermatitis: atopic dermatitis conference coverage from Clinical Care Options (CCO)
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
